DrCarney.com Blog
Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
The use of selective serotonin reuptake inhibitors (SSRIs) may heighten the risk of a woman's risk of dying prematurely from breast cancer.
This study assessed how the use of antidepressant medications in the class of selective serotonin reuptake inhibitors (SSRIs) influences the likelihood of dying from breast cancer. Researchers monitored the drug prescription and mortality records of 23,669 breast cancer patients.
Researchers noticed that the probability of dying from breast cancer was high among users of SSRIs compared to non users of antidepressant medications. According to this study, patients on SSRIs experienced a 27% increase in the risk of death due to breast cancer. This study suggests that breast cancer patients using SSRIs may face increased chances of suffering from early death resulting from the disease.
Research Summary Information
-
2018
-
Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR.
-
Centre for Public Health, Queen's University Belfast, Belfast, UK. john.busby@qub.ac.uk. Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, UK. Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, University of Ulster, C-TRIC Building, Altnagelvin Area Hospital, Londonderry, UK. Centre for Public Health, Queen's University Belfast, Belfast, UK.
-
Yes, Free full text of study was found:
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
About the author
